TABLE 3.

Associations of MyD88 and TLR4 Expression and Overall Survival Among HGSOC Cases by Extent of Residual Disease, by Pathogenic Mutation Status, and by First-Line Chemotherapy^a,^b

		MyD88					TLR4
Clinical attribute	Level	N	No. of events	HR (95% CI)	P	Level	N	No. of events	HR (95% CI)	P
Extent of residual disease
Macroscopic disease	Weak	274	202	Reference	.45	Weak	292	219	Reference	.08
	Strong	800	659	1.07 (0.90–1.27)		Strong	687	576	1.17 (0.98–1.39)
No macroscopic disease	Weak	185	92	Reference	.39	Weak	207	115	Reference	.03
	Strong	561	278	1.12 (0.87–1.44)		Strong	476	238	0.76 (0.59–0.97)
Pathogenic mutation status
Tested negative	Weak	152	90	Reference	.02	Weak	147	99	Reference	.16
	Strong	485	347	1.33 (1.04–1.70)		Strong	444	321	1.19 (0.94–1.51)
Pathogenic BRCA1 mutation	Weak	23	11	Reference	.70	Weak	27	10	Reference	.01
	Strong	82	50	1.18 (0.51–2.72)		Strong	71	43	2.69 (1.25–5.81)
Pathogenic BRCA2 mutation	Weak	13	4	Reference	.69	Weak	11	6	Reference	.02
	Strong	35	15	1.30 (0.36–4.71)		Strong	31	12	0.26 (0.08–0.84)
First-line chemotherapy treatment
Standard treatment	Weak	59	36	Reference	.27	Weak	102	62	Reference	.77
	Strong	280	176	1.24 (0.85–1.82)		Strong	231	150	0.96 (0.68–1.37)

^aAUC = area under the concentration-time curve; BRCA1 = breast cancer susceptibility gene 1; BRCA2 = breast cancer susceptibility gene 2; HGSOC = high-grade serous ovarian cancer; HR, hazard ratio; MyD88 = myeloid differentiation primary response gene 88; TLR4 = Toll-like receptor 4.

^bAdjusted for study, age (continuous), and stage (I/II, III/IV, unknown); mutation status reflects results of germline testing; standard treatment includes patients receiving ≥4 cycles of intravenous carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m² every 3 wk and patients receiving ≥4 cycles of intravenous carboplatin and paclitaxel every 3 wk with dose presumed to be carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m².